These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 1609193

  • 1. [Ex-vivo treatment of a bone marrow graft].
    Bieva CJ.
    Rev Med Brux; 1992 May; 13(5):177-82. PubMed ID: 1609193
    [Abstract] [Full Text] [Related]

  • 2. [Cellular sorting methods in autologous (elimination of residual malignant cells) or allogeneic (T lymphocyte elimination) bone marrow grafts. Clinical pilot studies].
    Hervé P, Flesch M.
    Nouv Rev Fr Hematol (1978); 1986 May; 28(2):97-105. PubMed ID: 2942838
    [Abstract] [Full Text] [Related]

  • 3. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma.
    Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, Grossbard ML, Rabinowe SN, Coral F, Freeman GJ.
    N Engl J Med; 1991 Nov 28; 325(22):1525-33. PubMed ID: 1944436
    [Abstract] [Full Text] [Related]

  • 4. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E, Nagler A, Or R, Kapelushnik J, Slavin S.
    Clin Transpl; 1996 Nov 28; ():281-90. PubMed ID: 9286578
    [Abstract] [Full Text] [Related]

  • 5. [Application of monoclonal antibodies to bone marrow transplantation].
    Morishima Y.
    Gan To Kagaku Ryoho; 1988 May 28; 15(5):1693-701. PubMed ID: 3285796
    [Abstract] [Full Text] [Related]

  • 6. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L, Lubin I, Factorowich I, Lapidot Z, Reich S, Reisner Y, Slavin S.
    J Immunol; 1994 Sep 15; 153(6):2562-7. PubMed ID: 8077666
    [Abstract] [Full Text] [Related]

  • 7. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD, Drobyski WR, Truitt RL.
    Bone Marrow Transplant; 1993 Apr 15; 11(4):329-36. PubMed ID: 8485480
    [Abstract] [Full Text] [Related]

  • 8. T-cell depletion and allogeneic bone marrow transplantation.
    O'Reilly RJ.
    Semin Hematol; 1992 Apr 15; 29(2 Suppl 1):20-6. PubMed ID: 1615341
    [No Abstract] [Full Text] [Related]

  • 9. [In vitro manipulation of bone marrow cells for bone marrow transplantation].
    Morishima Y.
    Gan To Kagaku Ryoho; 1988 Nov 15; 15(11):3034-43. PubMed ID: 3056275
    [Abstract] [Full Text] [Related]

  • 10. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
    Sao H, Kitaori K, Kasai M, Shimokawa T, Kato C, Yamanishi H, Ueda R, Morishima Y.
    Int J Hematol; 1999 Jan 15; 69(1):27-35. PubMed ID: 10641440
    [Abstract] [Full Text] [Related]

  • 11. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ, Mauch P, Fairclough D, Alyea E, Anderson K, Fisher D, Freedman A, Bartlett-Pandite L, Robertson M, Schlossman R, Gollob J, Marcus K, Murray C, Kuhlman C, Freeman A, Nadler L, Ritz J.
    Biol Blood Marrow Transplant; 1997 Apr 15; 3(1):11-7. PubMed ID: 9209736
    [Abstract] [Full Text] [Related]

  • 12. Bone marrow-resident memory T cells survive pretransplant chemotherapy and contribute to early immune reconstitution of patients with acute myeloid leukemia given mafosfamide-purged autologous bone marrow transplantation.
    Casorati G, Locatelli F, Pagani S, Garavaglia C, Montini E, Lisini D, Turin I, Rossi F, Dellabona P, Maccario R, Montagna D.
    Exp Hematol; 2005 Feb 15; 33(2):212-8. PubMed ID: 15676215
    [Abstract] [Full Text] [Related]

  • 13. Selective depletion of CD8-positive T-lymphocytes for allogeneic bone marrow transplantation: engraftment, graft-versus-host disease and graft-versus leukemia.
    Champlin R, Giralt S, Przepiorka D, Ho W, Lee K, Gajewski J, Nimer S, Andersson B, Wallerstein R, Ippolito C.
    Prog Clin Biol Res; 1992 Feb 15; 377():385-94; discussion 395-8. PubMed ID: 1438435
    [No Abstract] [Full Text] [Related]

  • 14. Influence of ultraviolet-B irradiation on engraftment, graft-versus-host disease and graft-versus-leukemia effect in a rat model for allogeneic bone marrow transplantation.
    Gowing H, Braakman E, Hagenbeek A, Lawler M, McCann SR, Pamphilon DH, Martens AC.
    Bone Marrow Transplant; 1998 Apr 15; 21(8):801-7. PubMed ID: 9603404
    [Abstract] [Full Text] [Related]

  • 15. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation.
    Keever-Taylor CA, Passweg J, Kawanishi Y, Casper J, Flomenberg N, Baxter-Lowe LA.
    Bone Marrow Transplant; 1997 May 15; 19(10):1001-9. PubMed ID: 9169644
    [Abstract] [Full Text] [Related]

  • 16. Autologous bone marrow transplantation for leukemia.
    Stuart RK.
    Semin Oncol; 1993 Oct 15; 20(5 Suppl 6):40-54. PubMed ID: 8211215
    [Abstract] [Full Text] [Related]

  • 17. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
    Weiss L, Reich S, Slavin S.
    Cytokines Cell Mol Ther; 1999 Sep 15; 5(3):145-52. PubMed ID: 10641572
    [Abstract] [Full Text] [Related]

  • 18. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?
    Slavin S, Ackerstein A, Naparstek E, Or R, Weiss L.
    Bone Marrow Transplant; 1990 Sep 15; 6(3):155-61. PubMed ID: 2252954
    [Abstract] [Full Text] [Related]

  • 19. Laboratory control in predicting clinical efficacy of T cell-depletion procedures used for prevention of graft-versus-host disease: importance of limiting dilution analysis.
    Marciniak E, Romond EH, Thompson JS, Henslee PJ.
    Bone Marrow Transplant; 1988 Nov 15; 3(6):589-98. PubMed ID: 3063328
    [Abstract] [Full Text] [Related]

  • 20. Allograft and autograft purging using immunotoxins in clinical bone marrow transplantation for hematologic malignancies.
    Uckun FM, Myers DE.
    J Hematother; 1993 Nov 15; 2(2):155-63. PubMed ID: 7921971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.